Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App





BD Receives FDA EUA for Asymptomatic Screening for SARS-CoV-2 Through Serial Rapid Antigen Testing

By LabMedica International staff writers
Posted on 02 Apr 2021
Becton, Dickinson and Company (BD Franklin Lakes, NJ, USA) has been granted Emergency Use Authorization (EUA) by the US Food and Drug Administration (FDA) for its rapid antigen test to be used for SARS-CoV-2 screening through serial testing of asymptomatic individuals.

The BD Veritor Plus System for Rapid Detection of SARS-CoV-2 is intended for the qualitative detection of SARS-CoV-2 nucleocapsid antigens in direct anterior nasal swabs from individuals who are either suspected of COVID-19 by their health care provider within the first five days of the onset of symptoms, or from individuals without symptoms or other epidemiological reasons to suspect COVID-19 when tested twice over two or three days with at least 24 hours and no more than 48 hours between tests. More...
The EUA for the BD Veritor Plus System includes SARS-CoV-2 screening through serial testing of asymptomatic individuals when tested twice over two or three days with at least 24 hours and no more than 48 hours between tests. Serial testing on the BD Veritor Plus System can be performed in any setting with a CLIA certificate of waiver.

"BD is supporting the global efforts to return to normalcy as soon as possible, and this additional authorization for the BD Veritor System to be used in screening through serial testing of asymptomatic individuals is a large step forward," said Dave Hickey, president of Life Sciences for BD. "Frequent testing of individuals without symptoms will enable those with negative results to resume their normal school or work routines and will help to identify and isolate positive cases of COVID-19 as early as possible to prevent further spread. Screening through serial testing is an important part of any back-to-school or back-to-work program, along with additional measures such as mask wearing and social distancing."

Related Links:
Becton, Dickinson and Company


Gold Member
SARS-CoV-2 Reactive & Non-Reactive Controls
Qnostics SARS-CoV-2 Typing
Collection and Transport System
PurSafe Plus®
New
Gold Member
Automated MALDI-TOF MS System
EXS 3000
New
Gold Member
Hybrid Pipette
SWITCH
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: New evidence shows viscoelastic testing can improve assessment of blood clotting during postpartum hemorrhage (Photo courtesy of 123RF)

Viscoelastic Testing Could Improve Treatment of Maternal Hemorrhage

Postpartum hemorrhage, severe bleeding after childbirth, remains one of the leading causes of maternal mortality worldwide, yet many of these deaths are preventable. Standard care can be hindered by delays... Read more

Immunology

view channel
Image: The tool enables scientists to track real-time fluctuations in T cell function with unprecedented speed and precision (Photo courtesy of Shutterstock)

Luminescent Probe Measures Immune Cell Activity in Real Time

The human immune system plays a vital role in defending against disease, but its activity must be precisely monitored to ensure effective treatment in cancer therapy, autoimmune disorders, and organ transplants.... Read more

Industry

view channel
Image: The collaboration supports clinical validation and regulatory submissions of the new T1D 4-plex assay on Revvity’s GSP instrument (Photo courtesy of Revvity)

Revvity and Sanofi Collaborate on Program to Revolutionize Early Detection of Type 1 Diabetes

Type 1 diabetes (T1D) is a lifelong autoimmune condition in which the immune system destroys the pancreas’s insulin-producing beta cells, leading to dependence on insulin therapy. Early detection is critical... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.